Table 2.

Patient characteristics from haematopoietic stem cell transplantation to thrombotic microangiopathy onset.

Pt No	From HSCT to TMA (days)	Complications at TMA onset			Primary disease condition at TMA onset	History of TMA	Family TMA history	Complement-related factors
		GVHD	VOD	Infection
1a	31	None	None	Fungal infection, CMV pneumonia	Ongoing	0	n/a	n/a
2a	32	Ongoing	Ongoing	FN	Ongoing	1	No	n/a
3	58	None	None	None	Ongoing	0	No	n/a
4a	26	Ongoing	None	None	Ongoing	0	No	n/a
5	19	Ongoing	Remission	FN	Ongoing	0	Yes	Anti-CFH antibody,
6a	21	Ongoing	Remission	None	Ongoing	0	Yes	Anti-CFH antibody,
7	20	-	None	FN	Ongoing	0	Yes	Het CFHR3-CFHR1 del
8	21	-	None	FN	Ongoing	0	No	n/a
9	62	Ongoing	Ongoing	None	Ongoing	0	No	n/d
10a	215	Ongoing	Ongoing	pulmonary aspergillosis	None	0	No	n/a
11a	323	Ongoing	None	CMV enterocolitis	None	1	No	n/d
12	18	None	None	None	None	0	No	FCN3 c.465 G > C
13	52	-	None	FN	None	0	No	n/a
Median (IQR), days	31 (21–58)

CFH complement factor H, CFHR complement factor H receptor, CMV cytomegalovirus, def deficiency, del deletion, EB Epstein–Barr, ECZ eculizumab, FCN3 ficolin 3, het heterozygous, GVHD graft-versus-host disease, HSCT haematopoietic stem cell transplantation, mut mutation, n/a not available, n/d not detected, PE plasma exchange, PI plasma infusion, Pt patient, TMA thrombotic microangiopathy, FN febrile neutropenia

^anon-survivors.